Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
Global Cancer Immunotherapy Market & Clinical Trials Outlook 2017-2022: Currently, there are more than 2 000 cancers immunotherapies based drugs/therapies in the clinical pipeline (ref www.clinicaltrials.gov and . Research is ongoing to combine check-point inhibitors (CPIs) with drugs that boost the immune system and it is generally believed that combination (therapies) treatments i.e. addition of immune regulatory/stimulatory agents have the potential to augment the response to CPIs, such as ISR´s lead drug immune stimulatory candidate ISR397.
Strategic alliances are one of the major trends being witnessed in the global immune checkpoint inhibitors market 2019-2023. The rise in prevalence of various types of cancers increases the demand for innovative therapeutics. Immune checkpoints inhibitor therapeutics is one of the most reliable therapeutic options for the treatment of cancer. This is the reason why many companies are associating for developing and marketing these drugs. Such strategic alliances and partnerships help to reach out a larger geographical area and result in higher ROI. Thus, the vendors in the global immune checkpoint inhibitors market are expected to continue exploring strategic ways to tap significant opportunity, thereby driving the market growth.
The companies leading the immuno-oncology charge believe combinations will bring the long survival durations their treatments offer to wider patient groups. With analysts forecasting that total annual revenues from immuno-oncology drugs will reach around $20–30 billion (£13–£19 billion) within a decade, these collaborations will help other firms to cash in too. And if the strategy benefits the many cancer types targeted, the boon to patients will be tempered by doubly expensive prescriptions that healthcare systems are yet to adapt to.
A complex web of collaborations is emerging as firms compete to understand and apply their drugs to different cancer types.
Merck bought half the rights to AstraZeneca’s Lynparza in a deal worth $8.5bn. The firms will co-develop and sell a drug known as a “PARP inhibitor”. It will be developed in combination with checkpoint inhibitors made by both firms.
Opdivo and Keytruda are the two best-selling checkpoint inhibitors. Opdivo made $4.9 billion in sales in 2017, while Keytruda made $3.8 billion.
ISR Oncology business is based on development of immunotherapies in the field of oncology. The lead drugs candidate ISR-050 is a derivative of an antibiotic compound from the family of macrolides. The ISR-050 family of compounds have essential functions stimulating the immune system and can be used either as single treatments or in combination with already existing and marketed immunotherapies in cancer.
ISR-050, as a potent immune stimulatory pharmaceutical agent, could be combined with any of the therapeutic regimens listed in the figure above.